Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2000 1
2003 1
2005 1
2016 1
2017 2
2018 1
2019 2
2020 1
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression.
Lakhia R, Ramalingam H, Chang CM, Cobo-Stark P, Biggers L, Flaten A, Alvarez J, Valencia T, Wallace DP, Lee EC, Patel V. Lakhia R, et al. Among authors: flaten a. Nat Commun. 2022 Aug 15;13(1):4765. doi: 10.1038/s41467-022-32543-2. Nat Commun. 2022. PMID: 35965273 Free PMC article.
A methionine-Mettl3-N6-methyladenosine axis promotes polycystic kidney disease.
Ramalingam H, Kashyap S, Cobo-Stark P, Flaten A, Chang CM, Hajarnis S, Hein KZ, Lika J, Warner GM, Espindola-Netto JM, Kumar A, Kanchwala M, Xing C, Chini EN, Patel V. Ramalingam H, et al. Among authors: flaten a. Cell Metab. 2021 Jun 1;33(6):1234-1247.e7. doi: 10.1016/j.cmet.2021.03.024. Epub 2021 Apr 13. Cell Metab. 2021. PMID: 33852874 Free PMC article.
Toxicity Management of Systemic Kidney Cancer Therapies.
Qin Q, Nein E, Flaten A, Zhang T. Qin Q, et al. Among authors: flaten a. Hematol Oncol Clin North Am. 2023 Oct;37(5):993-1003. doi: 10.1016/j.hoc.2023.05.006. Epub 2023 Jun 21. Hematol Oncol Clin North Am. 2023. PMID: 37353375 Review.
Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease.
Lee EC, Valencia T, Allerson C, Schairer A, Flaten A, Yheskel M, Kersjes K, Li J, Gatto S, Takhar M, Lockton S, Pavlicek A, Kim M, Chu T, Soriano R, Davis S, Androsavich JR, Sarwary S, Owen T, Kaplan J, Liu K, Jang G, Neben S, Bentley P, Wright T, Patel V. Lee EC, et al. Among authors: flaten a. Nat Commun. 2019 Sep 12;10(1):4148. doi: 10.1038/s41467-019-11918-y. Nat Commun. 2019. PMID: 31515477 Free PMC article.
microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism.
Hajarnis S, Lakhia R, Yheskel M, Williams D, Sorourian M, Liu X, Aboudehen K, Zhang S, Kersjes K, Galasso R, Li J, Kaimal V, Lockton S, Davis S, Flaten A, Johnson JA, Holland WL, Kusminski CM, Scherer PE, Harris PC, Trudel M, Wallace DP, Igarashi P, Lee EC, Androsavich JR, Patel V. Hajarnis S, et al. Among authors: flaten a. Nat Commun. 2017 Feb 16;8:14395. doi: 10.1038/ncomms14395. Nat Commun. 2017. PMID: 28205547 Free PMC article.
14 results